Heligenics Overview
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
5
Heligenics General Information
Description
Developer of a protein engineering platform designed to identify and optimize therapeutic proteins for drug development. The company offers high-throughput screening of protein variants, protein function data, and computational analysis, enabling biopharmaceutical companies and researchers to develop antibodies, interferons, and peptide-based therapeutics for cancer, autoimmune diseases, and metabolic disorders.
Contact Information
Website
www.heligenics.comCorporate Office
- 10530 Discovery Drive
- Las Vegas, NV 89135
- United States
Corporate Office
- 10530 Discovery Drive
- Las Vegas, NV 89135
- United States
Heligenics Timeline
Heligenics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Accelerator/Incubator | Completed | Startup | ||||
| 5. Later Stage VC | 08-Jan-2025 | Completed | Startup | |||
| 4. Grant | 02-Feb-2023 | Completed | Startup | |||
| 3. Seed Round | 23-Aug-2022 | Completed | Startup | |||
| 2. Seed Round | 15-Dec-2020 | $1.18M | $1.18M | Completed | Startup | |
| 1. Grant | 01-Jan-2015 | $2.5M | Completed | Startup |
Heligenics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-1 | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Heligenics Patents
Heligenics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025236991-A1 | Glycosylated engineered interferon beta proteins | Pending | 15-Mar-2024 | ||
| WO-2025194144-A2 | Glycosylated engineered interferon beta proteins | Pending | 15-Mar-2024 | ||
| WO-2025194144-A3 | Glycosylated engineered interferon beta proteins | Pending | 15-Mar-2024 | ||
| AU-2024341598-A1 | Engineered interferon-beta proteins | Pending | 12-Sep-2023 | ||
| EP-4777131-A2 | Engineered interferon-beta proteins | Pending | 12-Sep-2023 | C07K14/565 |
Heligenics Signals
Heligenics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| City of Las Vegas | Government | Minority | ||
| University of Nevada, Las Vegas Foundation | University | Minority | ||
| Battle Born Venture | Venture Capital | Minority | ||
| Nevada Governor's Office of Economic Development | Government | |||
| Roseman Bioventures | Accelerator/Incubator |
Heligenics FAQs
-
Where is Heligenics headquartered?
Heligenics is headquartered in Las Vegas, NV.
-
What is the size of Heligenics?
Heligenics has 7 total employees.
-
What industry is Heligenics in?
Heligenics’s primary industry is Drug Discovery.
-
Is Heligenics a private or public company?
Heligenics is a Private company.
-
What is Heligenics’s current revenue?
The current revenue for Heligenics is .
-
How much funding has Heligenics raised over time?
Heligenics has raised $5.97M.
-
Who are Heligenics’s investors?
City of Las Vegas, University of Nevada, Las Vegas Foundation, Battle Born Venture, Nevada Governor's Office of Economic Development, and Roseman Bioventures have invested in Heligenics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process